Development of a vaccine for toxoplasmosis: current status.
about
Changing climate-changing pathogens: Toxoplasma gondii in North-Western Europe.Effect of codon optimization and subcellular targeting on Toxoplasma gondii antigen SAG1 expression in tobacco leaves to use in subcutaneous and oral immunization in mice.Sero-diagnostic evaluation of Toxoplasma gondii recombinant Rhoptry antigen 8 expressed in E. coliA novel PAN/apple domain-containing protein from Toxoplasma gondii: characterization and receptor identificationDNA vaccination with a gene encoding Toxoplasma gondii Deoxyribose Phosphate Aldolase (TgDPA) induces partial protective immunity against lethal challenge in miceToxoplasma gondii cathepsin proteases are undeveloped prominent vaccine antigens against toxoplasmosis.Parasite distribution and associated immune response during the acute phase of Toxoplasma gondii infection in sheepComparison of protective immune responses to apicomplexan parasitesEvaluation of Toxoplasma gondii as a live vaccine vector in susceptible and resistant hosts.Prime-boost vaccination with toxoplasma lysate antigen, but not with a mixture of recombinant protein antigens, leads to reduction of brain cyst formation in BALB/c mice.Virus-Like Nanoparticle Vaccine Confers Protection against Toxoplasma gondii.Improvement and Evaluation of Loop-Mediated Isothermal Amplification for Rapid Detection of Toxoplasma gondii Infection in Human Blood Samples.Molecular cloning and characterization of a matrix metalloproteinase, from Caenorhabditis elegans: employed to identify homologous protein from Angiostrongylus cantonensis.Induction of long-lasting protective immunity against Toxoplasma gondii in BALB/c mice by recombinant surface antigen 1 protein encapsulated in poly (lactide-co-glycolide) microparticles.Evaluation of Immunoprotection Conferred by the Subunit Vaccines of GRA2 and GRA5 against Acute Toxoplasmosis in BALB/c Mice.Identification and characterization of Toxoplasma gondii aspartic protease 1 as a novel vaccine candidate against toxoplasmosis.Protective immune response in BALB/c mice induced by DNA vaccine of the ROP8 gene of Toxoplasma gondiiDietary supplementation of mannan-oligosaccharide enhances neonatal immune responses in chickens during natural exposure to Eimeria sppVaccination concepts against Toxoplasma gondii.The genome of the protozoan parasite Cystoisospora suis and a reverse vaccinology approach to identify vaccine candidates.Review on the identification and role of Toxoplasma gondii antigenic epitopes.The protective effect of a DNA vaccine encoding the Toxoplasma gondii cyclophilin gene in BALB/c mice.Analysis of structures and epitopes of a novel secreted protein MYR1 in Toxoplasma gondii.Kinetics and phenotype of vaccine-induced CD8+ T-cell responses to Toxoplasma gondii.Specific, sensitive, and rapid diagnosis of active toxoplasmosis by a loop-mediated isothermal amplification method using blood samples from patients.Molecular cloning, sequencing, and biological characterization of GRA4 gene of Toxoplasma gondii.Multicomponent DNA vaccine-encoding Toxoplasma gondii GRA1 and SAG1 primes: anti-Toxoplasma immune response in mice.Elevated Expression of indoleamine 2,3-dioxygenase (IDO) and accumulation of kynurenic acid in the pathogenesis of STZ-induced diabetic cataract in Wistar rats.Immunological interaction between Giardia cyst extract and experimental toxoplasmosis.Evaluation of the Protective Effect of Deoxyribonucleic Acid Vaccines Encoding Granule Antigen 2 and 5 Against Acute Toxoplasmosis in BALB/c Mice.Comparing the effect of IL-12 genetic adjuvant and alum non-genetic adjuvant on the efficiency of the cocktail DNA vaccine containing plasmids encoding SAG-1 and ROP-2 of Toxoplasma gondii.Immunogenic characterization of the chimeric surface antigen 1 and 2 (SAG1/2) of Toxoplasma gondii expressed in the yeast Pichia pastorisDevelopment and characterization of a formulation based covalent conjugation with polyacrylic acid and recombinant major surface antigen (SAG1) of Toxoplasma gondii
P2860
Q33439718-C1158550-7A91-404D-A008-202738ADF8B4Q33633418-E3E4F014-3E4A-4ECE-AF27-324447EA0CF9Q33902694-B117E33B-68B0-4693-9A91-5D92292AC7B8Q34140376-EA950C0D-3CE2-4DBD-AB03-04F4A3FB79A2Q34184744-7E1124BA-270D-41A6-BFEC-1AE1CAB56864Q34709118-25A21A68-100C-4B0D-8150-88530209DB90Q34788148-9F8B9E00-913A-4C6C-B66D-20EC9A038940Q35173273-B98F36D5-5EE3-40B8-89DB-2FB0D983C36BQ35225633-B36660CB-703C-4041-AECD-423494AE7B14Q35641195-6F039D48-1F59-4534-95C9-3C593373F502Q36109262-88539E3A-CCA7-47A7-855A-2420833629C0Q36240470-613B97D1-82FA-45FA-9CEB-B08AE3ACBEC6Q36345506-CB0CB98B-F5F3-426E-8EB7-DC5903E16C0AQ36646902-62CCDD29-F512-4E95-86AF-BD94D44C4EDAQ36843269-C2455ABE-EF81-45A3-A823-1FB2D90123C3Q36952854-6473B038-D449-4DC4-9058-5CC81C656728Q37119395-4C037DE7-9B08-443C-8A93-AE064758373BQ37154858-C9A772FA-4517-48BA-B20F-08EBA4E01B6DQ37386300-15C353CA-FC76-4773-A937-E077B56D8FF5Q37705239-216B073A-7C95-4FBF-BF0C-4596EDA6BDBCQ38637651-BC663FAF-0EFA-4CBF-B42B-9B99DB12C83FQ39493471-344A700B-F571-4414-ABC7-C91497CB95C1Q40556517-9DD11209-FAED-4A45-AD0F-616782D72978Q41850308-E0667FC8-ACF4-4ED4-801E-2A82BC5A7AA9Q42076435-399CF779-E2DA-4DF4-8558-7E0C01F80369Q42594463-6AC37079-A582-4A55-A0C2-44C57B7B1E84Q44241192-B60AD495-A6E5-4193-91B4-4E318BBB96B9Q46047612-08534087-5B74-40BF-9A3D-287F38BEB398Q46208643-9937C6A7-A0CE-404F-89E1-B3C65C4365C7Q50884140-854D692D-2CA6-438E-8896-A00338652F07Q51358760-9309CD40-E346-41D6-89A5-BF5D473F2695Q57269736-B628933C-C77E-4D05-926C-0EE30EEFF1AAQ57381700-3CFF4284-95D9-497E-89EC-06449B031441
P2860
Development of a vaccine for toxoplasmosis: current status.
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Development of a vaccine for toxoplasmosis: current status.
@ast
Development of a vaccine for toxoplasmosis: current status.
@en
type
label
Development of a vaccine for toxoplasmosis: current status.
@ast
Development of a vaccine for toxoplasmosis: current status.
@en
prefLabel
Development of a vaccine for toxoplasmosis: current status.
@ast
Development of a vaccine for toxoplasmosis: current status.
@en
P1476
Development of a vaccine for toxoplasmosis: current status.
@en
P2093
Girish M Bhopale
P304
P356
10.1016/S1286-4579(03)00048-0
P577
2003-04-01T00:00:00Z